Aug 2011 to 2000 Quality ManagerArrow Head Products Los Alamitos, CA Nov 2004 to Oct 2005 InspectorIndustrial Techtonics RBC Rancho Dominguez, CA Sep 1993 to May 2002 InspectorAnderson Greenwood, CO Mar 1990 to Jul 1993 InspectorAHF Ducommon Gardena, CA Aug 1987 to Feb 1990 Inspector
Education:
Compton Community College Compton, CA 1980 to 1982 N/A in General Education / Mechanical EngineeringDon Bosco Technical School Rosemead, CA Penetrant & Magnetic Particles
Charles L. Sawyers - Los Angeles CA Karen A. Klein - Los Angeles CA Owen N. Witte - Sherman Oaks CA Robert E. Reiter - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 6700
US Classification:
800 9, 435366, 424 937, 424 92, 424 9321
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Methods Of Simulating Human Prostate Cancer Progression
Charles L. Sawyers - Los Angeles CA Karen A. Klein - Los Angeles CA Owen N. Witte - Sherman Oaks CA Robert E. Reiter - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 6700
US Classification:
800 10, 424 92, 424 937, 800 8, 800 9, 800 18
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Charles L. Sawyers - Los Angeles CA Karen A. Klein - Los Angeles CA Owen N. Witte - Sherman Oaks CA Robert E. Reiter - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 6700
US Classification:
800 10, 800 8, 800 18
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Methods Of Assessing The Effect Of A Gene Of Interest On Human Prostate Cancer Progression
Charles L. Sawyers - Los Angeles CA, US Karen A. Klein - Los Angeles CA, US Owen N Witte - Sherman Oaks CA, US Robert E. Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K067/00 A01K063/00 C12N005/08 A61K049/00
US Classification:
800 3, 800 8, 800 9, 435366, 424 92, 424 9321
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Charles L Sawyers - Los Angeles CA, US Karen A. Klein - Los Angeles CA, US Owen N. Witte - Sherman Oaks CA, US Robert E Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K067/00 A01K067/033 A01K067/027
US Classification:
800 10, 800 8, 800 18
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
E25A Protein, Methods For Producing And Use Thereof
Robert E. Reiter - Los Angeles CA, US Owen N. Witte - Sherman Oaks CA, US Charles L. Sawyers - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07H 21/04 C12P 21/06 C12N 1/20 C12N 15/00
US Classification:
536 231, 435 691, 4353201, 4352521
Abstract:
The invention provides a human E25a protein which is upregulated in cancerous cells, including those of hormone refractory prostate cancer, colon cancer, breast cancer or other cancers of epithelial origin. The invention also provides nucleic acid molecules encoding E25a protein, nucleic acid probes which hybridize with nucleic acid molecules encoding E25a protein, and antibodies which bind E25a protein. E25a protein and its related molecules can be useful as diagnostic markers of cancer, including hormone refractory prostate cancer, and as specific therapeutic targets in this disease. The invention also provides methods for diagnosing cancer, including hormone refractory prostate cancer.
Charles L. Sawyers - Los Angeles CA, US Karen A. Klein - Los Angeles CA, US Owen N. Witte - Sherman Oaks CA, US Robert E. Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/10 A01K 67/00 A01K 67/33 A01K 67/27
US Classification:
800 9, 800 8, 800 10
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Charles L. Sawyers - Los Angeles CA, US Karen A. Klein - Los Angeles CA, US Owen N. Witte - Sherman Oaks CA, US Robert E. Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 67/00 A01N 63/00 A01N 65/00 A01K 67/027
US Classification:
800 10, 800 8, 800 9, 800 14, 800 18, 424 931
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
variable. People make these flippant comments that science is not reproducible. These first five papers show there are layers of complexity here that make it hard to say that, says Charles Sawyers, an eLife editor and cancer biologist at Memorial Sloan Kettering Cancer Center in New York City.
Date: Jan 18, 2017
Category: Health
Source: Google
Flatiron, Foundation Med Link Records of 20000 Cancer Patients
What you might consider a clunky manual method is also a very efficient way to ask and answer questions, rather than extracting everything from medical records and analyzing it later, says Charles Sawyers, a leading cancer researcher at Memorial Sloan Kettering who is leading GENIE. Id love a me
Date: Nov 03, 2016
Category: Health
Source: Google
Cancer drug discovered by UCLA sets off takeover fight among biotech companies
Work on the drug began at UCLA in the early 2000s when Charles Sawyers, then a professor of medicine at the university as well as an investigator at the Howard Hughes Medical Institute, identified why prostate cancer may fail to respond to first-generation cancer drugs.
Date: Jul 06, 2016
Category: Business
Source: Google
UCLA will get hundreds of millions for rights to prostate cancer drug
The research on Xtandi was led by chemist Michael Jung, who has been at UCLA since 1974, and Dr. Charles Sawyers, now at the Memorial Sloan Kettering Cancer Center in New York. The two men and six other researchers will share equally in the proceeds from their 37.5% stake in the drug's royalty inter
Date: Mar 04, 2016
Category: Health
Source: Google
Rights To UCLA-Developed Prostate Cancer Drug Sold For $1.14B
Research into the drug began in the early 2000s and was conducted by teams led by Michael Jung, a professor of chemistry and biochemistry, and Dr. Charles Sawyers, a former professor of medicine urology and pharmacology and a researcher at UCLAs Jonsson Comprehensive Cancer Center. Sawyers is now a
Date: Mar 04, 2016
Category: Health
Source: Google
Link found between breast-cancer genes, prostate cancer
Previous studies had turned up such mutations in a small fraction of men with early-stage disease, but we had no idea they were that common in advanced prostate cancer, said Charles Sawyers, chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center and one of t
Date: May 22, 2015
Category: Health
Source: Google
Seragon Pharmaceuticals Announces Acquisition Agreement With Genentech
I would also like to thank Dr. Charles Sawyers for his foundational work helping to elucidate the molecular determinants of resistance for hormone dependent prostate cancer. This is an ideal path, which will hopefully translate to improving the lives of patients," said Peter Svennilson, Founder and
Date: Jul 02, 2014
Category: Business
Source: Google
Reality Check on Cancer: Fast Progress But Too Many Preventable Deaths
e are finally seeing the payoff of investments over the past ten to 30 years that built up a body of knowledge about the underpinnings and root causes of cancer, says Dr. Charles Sawyers, president of AACR and chair of human oncology and pathogenesis at Memorial Sloan Kettering Cancer Center.